lawsuits
Class Action Lawsuit Filed Against ADMA Biologics, Inc. for Securities Violations
A class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) alleging violations of securities laws. The lawsuit was announced by the DJS Law Group and pertains to alleged misconduct under the Securities Exchange Act of 1934.
AS1 NewsSource: prnewswire.com
The DJS Law Group has announced a class action lawsuit against ADMA Biologics, Inc., a NASDAQ-listed biopharmaceutical company. The lawsuit alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, along with Rule 10b-5. The legal action claims that the company engaged in securities law violations, which could impact investor confidence and the company's stock performance. The lawsuit is part of ongoing legal proceedings and is intended to address alleged misconduct by the company.
ADMA Biologics, which specializes in plasma-derived biologics, has not yet issued a public response to the lawsuit. The case highlights potential legal risks for the company and may influence investor sentiment and market perception.
This development is relevant for shareholders, potential investors, and market analysts monitoring ADMA's regulatory and legal environment. The outcome of the lawsuit could have implications for the company's stock and its reputation in the biotech sector.
The lawsuit could pose legal and reputational risks to ADMA Biologics, potentially affecting its stock performance and investor confidence.